Analysts expect that Adaptimmune Therapeutics PLC (NASDAQ:ADAP) will post sales of $3.14 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Adaptimmune Therapeutics PLC’s earnings, with the lowest sales estimate coming in at $2.92 million and the highest estimate coming in at $3.50 million. Adaptimmune Therapeutics PLC posted sales of $2.42 million in the same quarter last year, which suggests a positive year-over-year growth rate of 29.8%. The business is scheduled to report its next earnings report on Thursday, November 9th.

On average, analysts expect that Adaptimmune Therapeutics PLC will report full year sales of $3.14 million for the current year, with estimates ranging from $12.21 million to $15.00 million. For the next financial year, analysts forecast that the firm will post sales of $17.42 million per share, with estimates ranging from $11.67 million to $30.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that follow Adaptimmune Therapeutics PLC.

Adaptimmune Therapeutics PLC (NASDAQ:ADAP) last issued its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.24) earnings per share for the quarter, hitting the consensus estimate of ($0.24). Adaptimmune Therapeutics PLC had a negative return on equity of 38.73% and a negative net margin of 438.00%. The business had revenue of $3.52 million for the quarter, compared to analyst estimates of $5.43 million.

Several analysts recently commented on the stock. BidaskClub upgraded shares of Adaptimmune Therapeutics PLC from a “strong sell” rating to a “sell” rating in a report on Saturday, July 8th. Cowen and Company reaffirmed a “buy” rating on shares of Adaptimmune Therapeutics PLC in a research report on Tuesday, June 6th. Zacks Investment Research lowered shares of Adaptimmune Therapeutics PLC from a “buy” rating to a “hold” rating in a research note on Monday, July 17th. ValuEngine upgraded shares of Adaptimmune Therapeutics PLC from a “strong sell” rating to a “sell” rating in a research note on Thursday, July 20th. Finally, Leerink Swann reiterated an “outperform” rating and issued a $15.00 target price on shares of Adaptimmune Therapeutics PLC in a research report on Friday, September 8th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $10.13.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.watchlistnews.com/adaptimmune-therapeutics-plc-adap-expected-to-post-quarterly-sales-of-3-14-million/1603993.html.

Hedge funds have recently modified their holdings of the business. AXA acquired a new position in Adaptimmune Therapeutics PLC in the 1st quarter worth about $4,959,000. Alps Advisors Inc. raised its stake in shares of Adaptimmune Therapeutics PLC by 4.9% during the 2nd quarter. Alps Advisors Inc. now owns 63,892 shares of the biotechnology company’s stock worth $287,000 after purchasing an additional 2,996 shares in the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of Adaptimmune Therapeutics PLC during the 1st quarter worth about $2,883,000. Raymond James Financial Services Advisors Inc. acquired a new stake in shares of Adaptimmune Therapeutics PLC during the 1st quarter valued at about $120,000. Finally, Renaissance Technologies LLC lifted its holdings in shares of Adaptimmune Therapeutics PLC by 75.4% during the 1st quarter. Renaissance Technologies LLC now owns 780,800 shares of the biotechnology company’s stock valued at $4,302,000 after buying an additional 335,700 shares during the last quarter. 68.01% of the stock is currently owned by institutional investors.

Adaptimmune Therapeutics PLC (ADAP) traded up 6.35% during midday trading on Friday, reaching $8.71. The company’s stock had a trading volume of 476,125 shares. The firm’s market capitalization is $616.62 million. Adaptimmune Therapeutics PLC has a 12 month low of $3.76 and a 12 month high of $9.29. The stock’s 50-day moving average price is $8.44 and its 200-day moving average price is $8.44.

About Adaptimmune Therapeutics PLC

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.

Get a free copy of the Zacks research report on Adaptimmune Therapeutics PLC (ADAP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.